Drugs / CPT31
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04672083 | Nov 2020 → Apr 2021 | HIV infectious disease | Navigen, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPT31 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04672083 ↗ |
| Action | Inhibit | “HIV entry inhibitor CPT31” NCT04672083 ↗ |
| Modality | Peptide | “novel D-peptide HIV entry inhibitor” NCT04672083 ↗ |
| Route | Subcutaneous | “single subcutaneous (SC) dose study” NCT04672083 ↗ |